Enhanced CAR-T Cell Therapy with Artificial Antigenic Epitope

An improved CAR-T cell therapy approach utilizing an optimized artificial antigenic epitope to enhance central memory T cell (Tcm) yield, persistence, and therapeutic efficacy, addressing limitations in existing CAR-T cell manufacturing and treatment.

The original patent, 'Method for preparing CAR-T cell with TCM as main active component and use thereof,' demonstrated the potential of CAR-T cell therapy using central memory T cells (Tcm). However, the existing approach faces challenges in achieving high Tcm yields, persistence, and therapeutic efficacy. The new inventive concept addresses these limitations by introducing an optimized artificial antigenic epitope, strategically located in the extracellular domain of the CAR, to enhance Tcm activation, growth, and survival.

The enhanced CAR-T cell therapy approach comprises a CAR with an artificial antigenic epitope optimized for binding affinity, located in the extracellular domain. This epitope selectively activates Tcm cells, promoting their growth, differentiation, and survival. The system further includes a bioreactor with a controlled environment for optimized Tcm cell growth and differentiation. Additionally, the invention encompasses a method for monitoring CAR-T cell therapy by detecting the expression of a biomarker associated with Tcm cell activation. This biomarker is selectively induced by the artificial antigenic epitope, enabling real-time assessment of therapy efficacy.

The new inventive concept introduces an optimized artificial antigenic epitope, strategically located in the extracellular domain of the CAR, which enhances Tcm activation, growth, and survival. This epitope, combined with the controlled bioreactor environment and biomarker-based monitoring, provides a novel and non-obvious solution to the limitations of existing CAR-T cell therapy approaches.

Alternative embodiments of the inventive concept may include varying the location of the artificial antigenic epitope within the CAR, using different types of antigen-presenting cells, or incorporating additional biomarkers for monitoring therapy efficacy. These variations can be implemented to broaden the scope of the inventive concept and adapt to diverse therapeutic applications.

The enhanced CAR-T cell therapy approach has significant commercial potential in the treatment of various cancers, including hematological malignancies and solid tumors. The target market includes pharmaceutical companies, biotechnology firms, and hospitals, with potential applications in personalized medicine, regenerative medicine, and immunotherapy.